Clonidine
- Generic Name
- Clonidine
- Brand Names
- Catapres, Catapres-TTS, Catapres-tts-1, Duraclon, Kapvay, Nexiclon XR
- Drug Type
- Small Molecule
- Chemical Formula
- C9H9Cl2N3
- CAS Number
- 4205-90-7
- Unique Ingredient Identifier
- MN3L5RMN02
- Background
Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors. This activity is useful for the treatment of hypertension, severe pain, and ADHD.
Clonidine was granted FDA approval on 3 September 1974.
- Indication
Clonidine tablets and transdermal systems are indicated for the treatment of hypertension alone or in combination with other medications. A clonidine injection is indicated for use with opiates in the treatment of severe cancer pain where opiates alone are insufficient. An extended release tablet of clonidine is indicated for the treatment of ADHD either alo...
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Defiant Disorder, Oppositional, Gilles de la Tourette's Syndrome, Hot Flashes, Human Growth Hormone Deficiency, Hypertension, Opioid Withdrawal (Disorder), Pheochromocytoma, Postherpetic Neuralgia, Sialorrhea caused by clozapine, Diabetic diarrhea, Methadone withdrawal, Severe Cancer pain
- Associated Therapies
- Smoking, Cessation
Sustained Release Excipients Market Size, Share | CAGR Of 8.5%
The Global Sustained Release Excipients Market is projected to grow from US$ 1.4 billion in 2023 to US$ 3.2 billion by 2033, driven by increasing demand for controlled drug delivery systems. North America leads with a 42.4% share, while advancements in nanotechnology and personalized medicine are set to propel market growth.
Onyda XR: New FDA-Approved Liquid Non-Stimulant for ADHD
Onyda XR, a liquid non-stimulant ADHD medication, became available nationwide on October 1. FDA approved it on May 24 for pediatric patients aged 6 and older, either as monotherapy or adjunctive therapy to CNS stimulants. Developed by Tris Pharma using LiquiXR® technology, Onyda XR is a centrally acting alpha2-adrenergic agonist, similar to Guanfacine and clonidine. Non-stimulant medications like Onyda XR are nearly as effective as stimulants in improving executive function, according to a May meta-analysis. Combination therapy with stimulants is increasingly popular for extended symptom coverage and reduced side effects.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath